{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:22:42Z","timestamp":1757618562399,"version":"3.44.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00108-025-01925-1","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:41:28Z","timestamp":1751017288000},"page":"702-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Fibrosehemmung am Beispiel der systemischen Sklerose","Pharmacological inhibition of fibrosis exemplified by systemic sclerosis"],"prefix":"10.1007","volume":"66","author":[{"given":"Tobias","family":"Dashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"5","key":"1925_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1172\/JCI131700","volume":"130","author":"T Maehara","year":"2020","unstructured":"Maehara\u00a0T, Kaneko\u00a0N, Perugino\u00a0CA, Mattoo\u00a0H, Kers\u00a0J, Allard-Chamard\u00a0H et\u00a0al (2020) Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J\u00a0Clin Invest 130(5):2451\u20132464","journal-title":"J Clin Invest"},{"issue":"6","key":"1925_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/art.40799","volume":"71","author":"A Lescoat","year":"2019","unstructured":"Lescoat\u00a0A, Yelnik\u00a0CM, Coiffier\u00a0G, Wargny\u00a0M, Lamotte\u00a0C, Cazalets\u00a0C et\u00a0al (2019) Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A\u00a0Multicenter Cross-Sectional Study. Arthritis Rheumatol 71(6):983\u2013990","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"1925_CR3","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni\u00a0SS, Santillo\u00a0M, Bevilacqua\u00a0F, Luchetti\u00a0M, Spadoni\u00a0T, Mancini\u00a0M et\u00a0al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N\u00a0Engl J Med 354(25):2667\u20132676","journal-title":"N Engl J Med"},{"issue":"3","key":"1925_CR4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/ard.2010.135772","volume":"70","author":"G Riemekasten","year":"2011","unstructured":"Riemekasten\u00a0G, Philippe\u00a0A, N\u00e4ther\u00a0M, Slowinski\u00a0T, M\u00fcller\u00a0DN, Heidecke\u00a0H et\u00a0al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70(3):530\u2013536","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1925_CR5","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar4503","volume":"16","author":"J G\u00fcnther","year":"2014","unstructured":"G\u00fcnther\u00a0J, Kill\u00a0A, Becker\u00a0MO, Heidecke\u00a0H, Rademacher\u00a0J, Siegert\u00a0E et\u00a0al (2014) Angiotensin receptor type\u00a01 and endothelin receptor type\u00a0A on immune cells mediate migration and the expression of IL\u20118 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 16(2):R65","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1925_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug\u00a0B, Khanna\u00a0D, Swindell\u00a0WR, Hinchcliff\u00a0ME, Frech\u00a0TM, Steen\u00a0VD et\u00a0al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a\u00a0prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79(3):379\u2013386","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1925_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler\u00a0JHW, Gyorfi\u00a0AH, Ramanujam\u00a0M, Whitfield\u00a0ML, Konigshoff\u00a0M, Lafyatis\u00a0R (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15(12):705\u2013730","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1925_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn\u00a0TA, Vannella\u00a0KM (2016) Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity 44(3):450\u2013462","journal-title":"Immunity"},{"issue":"7","key":"1925_CR9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.41243","volume":"72","author":"R Bhandari","year":"2020","unstructured":"Bhandari\u00a0R, Ball\u00a0MS, Martyanov\u00a0V, Popovich\u00a0D, Schaafsma\u00a0E, Han\u00a0S et\u00a0al (2020) Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis Rheumatol 72(7):1160\u20131169","journal-title":"Arthritis Rheumatol"},{"key":"1925_CR10","doi-asserted-by":"publisher","first-page":"341308","DOI":"10.1155\/2015\/341308","volume":"2015","author":"I Malyshev","year":"2015","unstructured":"Malyshev\u00a0I, Malyshev\u00a0Y (2015) Current Concept and Update of the Macrophage Plasticity Concept: Intracellular Mechanisms of Reprogramming and M3 Macrophage \u201cSwitch\u201d Phenotype. Biomed Res Int 2015:341308","journal-title":"Biomed Res Int"},{"issue":"7744","key":"1925_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-019-0896-x","volume":"566","author":"T Wohlfahrt","year":"2019","unstructured":"Wohlfahrt\u00a0T, Rauber\u00a0S, Uebe\u00a0S, Luber\u00a0M, Soare\u00a0A, Ekici\u00a0A (2019) PU.1 controls fibroblast polarization and tissue fibrosis. Nature 566(7744):344\u2013349","journal-title":"Nature"},{"issue":"6","key":"1925_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jid.2016.01.036","volume":"136","author":"M Mastrogiannaki","year":"2016","unstructured":"Mastrogiannaki\u00a0M, Lichtenberger\u00a0BM, Reimer\u00a0A, Collins\u00a0CA, Driskell\u00a0RR, Watt\u00a0FM (2016) \u03b2\u2011Catenin Stabilization in Skin Fibroblasts Causes Fibrotic Lesions by Preventing Adipocyte Differentiation of the Reticular Dermis. J\u00a0Invest Dermatol 136(6):1130\u20131142","journal-title":"J Invest Dermatol"},{"key":"1925_CR13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201916","author":"AH Gy\u00f6rfi","year":"2021","unstructured":"Gy\u00f6rfi\u00a0AH, Matei\u00a0AE, Fuchs\u00a0M, Liang\u00a0C, Rigau\u00a0AR, Hong\u00a0X et\u00a0al (2021) Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. J\u00a0Exp Med. https:\/\/doi.org\/10.1084\/jem.20201916","journal-title":"J Exp Med"},{"issue":"3","key":"1925_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41584-024-01217-2","volume":"21","author":"DJ Abraham","year":"2025","unstructured":"Abraham\u00a0DJ, Black\u00a0CM, Denton\u00a0CP, Distler\u00a0JHW, Domsic\u00a0R, Feghali-Bostwick\u00a0C et\u00a0al (2025) An international perspective on the future of systemic sclerosis research. Nat Rev Rheumatol 21(3):174\u2013187","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1925_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jid.2023.09.288","volume":"144","author":"H Zhu","year":"2024","unstructured":"Zhu\u00a0H, Luo\u00a0H, Skaug\u00a0B, Tabib\u00a0T, Li\u00a0YN, Tao\u00a0Y et\u00a0al (2024) Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features. J\u00a0Invest Dermatol 144(6):1251\u20131261.e1","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1925_CR16","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","volume":"12","author":"T Tabib","year":"2021","unstructured":"Tabib\u00a0T, Huang\u00a0M, Morse\u00a0N, Papazoglou\u00a0A, Behera\u00a0R, Jia\u00a0M et\u00a0al (2021) Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin. Nat Commun 12(1):4384","journal-title":"Nat Commun"},{"issue":"12","key":"1925_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard-2023-224184","volume":"82","author":"KEN Clark","year":"2023","unstructured":"Clark\u00a0KEN, Xu\u00a0S, Attah\u00a0M, Ong\u00a0VH, Buckley\u00a0CD, Denton\u00a0CP (2023) Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups. Ann Rheum Dis 82(12):1568\u20131579","journal-title":"Ann Rheum Dis"},{"key":"1925_CR18","first-page":"632962","volume":"2025.01.14","author":"Z Li","year":"2025","unstructured":"Li\u00a0Z, Rigau\u00a0AR, Xie\u00a0W, Shao\u00a0X, Li\u00a0Y\u2011N, Matei\u00a0A\u2011E et\u00a0al (2025) Mapping spatially-resolved transcriptomes in systemic sclerosis. bioRxiv 2025.01.14:632962","journal-title":"bioRxiv"},{"key":"1925_CR19","first-page":"630505","volume":"2024.12.28","author":"Y-N Li","year":"2024","unstructured":"Li\u00a0Y\u2011N, Filla\u00a0T, Gy\u00f6rfi\u00a0A\u2011H, Liang\u00a0M, Devakumar\u00a0V, Micu\u00a0A et\u00a0al (2024) Spatially informed phenotyping by cyclic-in-situ-hybridization identifies novel fibroblast populations and their pathogenic niches in systemic sclerosis. bioRxiv 2024.12.28:630505","journal-title":"bioRxiv."},{"key":"1925_CR20","doi-asserted-by":"crossref","unstructured":"Rius Rigau A, Liang M, Devakumar V, Neelagar R, Matei AE, Gy\u00f6rfi AH et\u00a0al (2024) Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosis. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2024-eular.2974"},{"issue":"7","key":"1925_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIRCRESAHA.123.323299","volume":"134","author":"A Rius Rigau","year":"2024","unstructured":"Rius Rigau\u00a0A, Li\u00a0YN, Matei\u00a0AE, Gy\u00f6rfi\u00a0AH, Bruch\u00a0PM, Koziel\u00a0S et\u00a0al (2024) Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics. Circ Res 134(7):875\u2013891","journal-title":"Circ Res"},{"issue":"6","key":"1925_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/01.bor.0000137894.63091.1a","volume":"16","author":"J Pannu","year":"2004","unstructured":"Pannu\u00a0J, Trojanowska\u00a0M (2004) Recent advances in fibroblast signaling and biology in scleroderma. Current Opinion in Rheumatology 16(6):739-745. https:\/\/doi.org\/10.1097\/01.bor.0000137894.63091.1a","journal-title":"Current Opinion in Rheumatology"},{"issue":"2","key":"1925_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/labinvest.2015.154","volume":"96","author":"C Bergmann","year":"2016","unstructured":"Bergmann\u00a0C, Distler\u00a0JH (2016) Canonical Wnt signaling in systemic sclerosis. Lab Invest 96(2):151\u2013155","journal-title":"Lab Invest"},{"issue":"1","key":"1925_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-012-1304-7","volume":"305","author":"C Beyer","year":"2013","unstructured":"Beyer\u00a0C, Dees\u00a0C, Distler\u00a0JH (2013) Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Arch Dermatol Res 305(1):1\u20138","journal-title":"Arch Dermatol Res"},{"key":"1925_CR25","doi-asserted-by":"crossref","unstructured":"Huynh LK, Hipolito CJ, Ten Dijke P (2019) A\u00a0Perspective on the Development of TGF\u2011\u03b2 Inhibitors for Cancer Treatment. Biomolecules 9(11)","DOI":"10.3390\/biom9110743"},{"key":"1925_CR26","doi-asserted-by":"crossref","unstructured":"Fakhouri SC, Zhu H, Li YN, Ronicke M, Rigau AR, Dees C et\u00a0al (2024) Disturbed Spatial WNT Activation\u2014A Potential Driver of the Reticularized Skin Phenotype in Systemic Sclerosis. Arthritis Rheumatol","DOI":"10.1002\/art.43094"},{"issue":"Si","key":"1925_CR27","first-page":"Si12","volume":"62","author":"E Romano","year":"2023","unstructured":"Romano\u00a0E, Rosa\u00a0I, Fioretto\u00a0BS, Giuggioli\u00a0D, Manetti\u00a0M, Matucci-Cerinic\u00a0M (2023) Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells. Baillieres Clin Rheumatol 62(Si):Si12\u2013si37 (Oxford)","journal-title":"Baillieres Clin Rheumatol"},{"issue":"7","key":"1925_CR28","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","volume":"74","author":"C Beyer","year":"2015","unstructured":"Beyer\u00a0C, Zenzmaier\u00a0C, Palumbo-Zerr\u00a0K, Mancuso\u00a0R, Distler\u00a0A, Dees\u00a0C et\u00a0al (2015) Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling. Ann Rheum Dis 74(7):1408\u20131416","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1925_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/art.42979","volume":"77","author":"C Bergmann","year":"2025","unstructured":"Bergmann\u00a0C, Chenguiti Fakhouri\u00a0S, Trinh-Minh\u00a0T, Filla\u00a0T, Rius Rigau\u00a0A, Ekici\u00a0AB et\u00a0al (2025) Mutual Amplification of GLI2\/Hedgehog and Transcription Factor JUN\/AP\u20111 Signaling in Fibroblasts in Systemic Sclerosis: Potential Implications for Combined Therapies. Arthritis Rheumatol 77(1):92\u201398","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1925_CR30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin\u00a0L, Wex\u00a0E, Pautsch\u00a0A, Schnapp\u00a0G, Hostettler\u00a0KE, Stowasser\u00a0S et\u00a0al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir\u00a0J 45(5):1434\u20131445","journal-title":"Eur Respir J"},{"key":"1925_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","volume":"72","author":"N Bellamri","year":"2019","unstructured":"Bellamri\u00a0N, Morzadec\u00a0C, Joannes\u00a0A, Lecureur\u00a0V, Wollin\u00a0L, Jouneau\u00a0S et\u00a0al (2019) Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. Int Immunopharmacol 72:112\u2013123","journal-title":"Int Immunopharmacol"},{"issue":"26","key":"1925_CR32","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M, Azuma\u00a0A, Fischer\u00a0A, Mayes\u00a0MD et\u00a0al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N\u00a0Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"},{"issue":"1","key":"1925_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland\u00a0KB, Distler\u00a0O, Kuwana\u00a0M, Allanore\u00a0Y, Assassi\u00a0S, Azuma\u00a0A et\u00a0al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a\u00a0subgroup analysis of the SENSCIS trial. Lancet Respir Med 9(1):96\u2013106","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1925_CR34","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2022-222564","volume":"81","author":"Y Allanore","year":"2022","unstructured":"Allanore\u00a0Y, Vonk\u00a0MC, Distler\u00a0O, Azuma\u00a0A, Mayes\u00a0MD, Gahlemann\u00a0M et\u00a0al (2022) Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis 81(12):1722\u20131729","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1925_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","volume":"7","author":"B Crestani","year":"2019","unstructured":"Crestani\u00a0B, Huggins\u00a0JT, Kaye\u00a0M, Costabel\u00a0U, Glaspole\u00a0I, Ogura\u00a0T et\u00a0al (2019) Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med 7(1):60\u201368","journal-title":"Lancet Respir Med"},{"key":"1925_CR36","doi-asserted-by":"crossref","unstructured":"Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, James A et\u00a0al (2025) Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3\u2011year data from SENSCIS-ON. Rmd Open 11(1)","DOI":"10.1136\/rmdopen-2024-005086"},{"issue":"1","key":"1925_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG, Bertoldo\u00a0E, Colic\u00a0J, Santiago\u00a0T et\u00a0al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1925_CR38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/acr.25348","volume":"76","author":"SR Johnson","year":"2023","unstructured":"Johnson\u00a0SR, Bernstein\u00a0EJ, Bolster\u00a0MB, Chung\u00a0JH, Danoff\u00a0SK, George\u00a0MD et\u00a0al (2023) American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (hoboken) 76(8):1051\u20131069","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"5","key":"1925_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells\u00a0AU, Flaherty\u00a0KR, Brown\u00a0KK, Inoue\u00a0Y, Devaraj\u00a0A, Richeldi\u00a0L et\u00a0al (2020) Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a\u00a0randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8(5):453\u2013460","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1925_CR40","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D, Albera\u00a0C, Fischer\u00a0A, Khalidi\u00a0N, Raghu\u00a0G, Chung\u00a0L et\u00a0al (2016) An Open-label, Phase\u00a0II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J\u00a0Rheumatol 43(9):1672\u20131679","journal-title":"J Rheumatol"},{"issue":"1","key":"1925_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon\u00a0JJ, Danoff\u00a0SK, Woodhead\u00a0FA, Hurwitz\u00a0S, Maurer\u00a0R, Glaspole\u00a0I et\u00a0al (2023) Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a\u00a0randomised, double-blind, placebo-controlled, phase\u00a02\u00a0study. Lancet Respir Med 11(1):87\u201396","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1925_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG, Bertoldo\u00a0E, \u010coli\u0107\u00a0J, Santiago\u00a0T et\u00a0al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1925_CR43","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ, Furst\u00a0DE, Khanna\u00a0D, Kleerup\u00a0EC et\u00a0al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1925_CR44","first-page":"1966","volume":"64","author":"E De Lorenzis","year":"2025","unstructured":"De Lorenzis\u00a0E, Natalello\u00a0G, Pellegrino\u00a0G, Verardi\u00a0L, Batani\u00a0V, Lepri\u00a0G et\u00a0al (2025) Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Baillieres Clin Rheumatol 64(4):1966\u20131974","journal-title":"Baillieres Clin Rheumatol"},{"issue":"7","key":"1925_CR45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh\u00a0D, Lin\u00a0CJF, Goldin\u00a0J, Kim\u00a0GH, Furst\u00a0DE, Denton\u00a0CP et\u00a0al (2021) Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 73(7):1301\u20131310","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1925_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Lin\u00a0CJF, van Laar\u00a0JM, Frech\u00a0TM, Anderson\u00a0ME et\u00a0al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a\u00a0phase\u00a0II randomised controlled trial (faSScinate). Ann Rheum Dis 77(2):212\u2013220","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1925_CR47","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE, Goldin\u00a0J, Kim\u00a0G, Kuwana\u00a0M et\u00a0al (2020) Tocilizumab in systemic sclerosis: a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Respir Med 8(10):963\u2013974","journal-title":"Lancet Respir Med"},{"key":"1925_CR48","doi-asserted-by":"crossref","unstructured":"Khanna D, Padilla C, Tsoi LC, Nagaraja V, Khanna PP, Tabib T et\u00a0al (2022) Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a\u00a0systemic sclerosis trial. JCI Insight 7(17)","DOI":"10.1172\/jci.insight.159566"},{"issue":"2","key":"1925_CR49","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2634","volume":"11","author":"N Hunzelmann","year":"2009","unstructured":"Hunzelmann\u00a0N, Moinzadeh\u00a0P, Genth\u00a0E, Krieg\u00a0T, Lehmacher\u00a0W, Melchers\u00a0I et\u00a0al (2009) High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 11(2):R30","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1925_CR50","first-page":"4364","volume":"61","author":"S Ebata","year":"2022","unstructured":"Ebata\u00a0S, Oba\u00a0K, Kashiwabara\u00a0K, Ueda\u00a0K, Uemura\u00a0Y, Watadani\u00a0T et\u00a0al (2022) Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a\u00a0machine-learning analysis of the DesiReS trial. Baillieres Clin Rheumatol 61(11):4364\u20134373","journal-title":"Baillieres Clin Rheumatol"},{"issue":"3","key":"1925_CR51","first-page":"1284","volume":"64","author":"G De Luca","year":"2025","unstructured":"De Luca\u00a0G, De Lorenzis\u00a0E, Campochiaro\u00a0C, Cacciapaglia\u00a0F, Del Papa\u00a0N, Zanatta\u00a0E et\u00a0al (2025) Rituximab retention rate in systemic sclerosis: a\u00a0long term real-life multicentre study. Baillieres Clin Rheumatol 64(3):1284\u20131291","journal-title":"Baillieres Clin Rheumatol"},{"key":"1925_CR52","doi-asserted-by":"crossref","unstructured":"Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P et\u00a0al (2023) Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a\u00a0double-blind, randomised, placebo-controlled trial. Eur Respir\u00a0J 61(6)","DOI":"10.1183\/13993003.02071-2022"},{"issue":"10","key":"1925_CR53","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00296-024-05695-1","volume":"44","author":"S Panopoulos","year":"2024","unstructured":"Panopoulos\u00a0S, Tzilas\u00a0V, Bournia\u00a0VK, Tektonidou\u00a0MG, Sfikakis\u00a0PP (2024) Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a\u00a0one-year observational study. Rheumatol Int 44(10):1959\u20131966","journal-title":"Rheumatol Int"},{"issue":"4","key":"1925_CR54","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ard.2025.01.014","volume":"84","author":"Q Yan","year":"2025","unstructured":"Yan\u00a0Q, Bruni\u00a0C, Garaiman\u00a0A, Mihai\u00a0C, Jordan\u00a0S, Becker\u00a0MO et\u00a0al (2025) Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Ann Rheum Dis 84(4):620\u2013631","journal-title":"Ann Rheum Dis"},{"key":"1925_CR55","doi-asserted-by":"crossref","unstructured":"Khanna D, de Vries-Bouwstra J, Hoffmann-Vold AM, Kuwana M, Low AHL, Proudman S et\u00a0al (2024) A\u00a0Phase\u00a0II study of avenciguat, a\u00a0novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE study. J\u00a0Scleroderma Relat Disord (23971983241291923)","DOI":"10.1177\/23971983241291923"},{"key":"1925_CR56","volume-title":"Avenciguat: a\u00a0novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis","author":"J Kaufman","year":"2025","unstructured":"Kaufman\u00a0J, Nabozny\u00a0G, Tran-Manh\u00a0C, Liebel\u00a0C, Zhou\u00a0X, Daley\u00a0LA et\u00a0al (2025) Avenciguat: a\u00a0novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN\u20111 signalling and fibrosis. Rheumatology, Oxford"},{"key":"1925_CR57","doi-asserted-by":"crossref","unstructured":"Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER (2024) Rationale for phosphodiesterase\u20114 inhibition as a\u00a0treatment strategy for interstitial lung diseases associated with rheumatic diseases. Rmd Open 10(4)","DOI":"10.1136\/rmdopen-2024-004704"},{"key":"1925_CR58","doi-asserted-by":"crossref","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ et\u00a0al (2023) Design of a\u00a0phase\u00a0III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respir Res 10(1)","DOI":"10.1136\/bmjresp-2022-001563"},{"key":"1925_CR59","doi-asserted-by":"crossref","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M et\u00a0al (2023) Design of a\u00a0phase\u00a0III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res 10(1)","DOI":"10.1136\/bmjresp-2022-001580"},{"issue":"22","key":"1925_CR60","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108\/BibUnstructured>","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi\u00a0L, Azuma\u00a0A, Cottin\u00a0V, Kreuter\u00a0M, Maher\u00a0TM, Martinez\u00a0FJ, Oldham\u00a0JM, et\u00a0al (2025) Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 392(22):2193\u20132202. https:\/\/doi.org\/10.1056\/NEJMoa2414108\/BibUnstructured>","journal-title":"N Engl J Med"},{"issue":"22","key":"1925_CR61","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher\u00a0TM, Assassi\u00a0S, Azuma\u00a0A, Cottin\u00a0V, Hoffmann-Vold\u00a0A-M, Kreuter\u00a0M, Oldham\u00a0JM, et\u00a0al (2025) Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med 392(22):2203\u20132214. https:\/\/doi.org\/10.1056\/NEJMoa2503643","journal-title":"N Engl J Med"},{"key":"1925_CR62","unstructured":"Boehringer Ingelheim (2024) Boehringer\u2019s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER\u2122-IPF study. https:\/\/www.boehringer-ingelheim.com\/us\/topline-results-boehringers-phase-iii-ipf-study. Zugegriffen: 01.2025"},{"key":"1925_CR63","unstructured":"A\u00a0Phase\u00a02\/3 (2023) Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD) (Internet). https:\/\/clinicaltrials.gov\/study\/NCT05878717"},{"key":"1925_CR64","unstructured":"(2024) An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) (Internet). https:\/\/clinicaltrials.gov\/study\/NCT06716606"},{"issue":"8","key":"1925_CR65","first-page":"1635","volume":"42","author":"D Khanna","year":"2024","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Assassi\u00a0S, Kuwana\u00a0M, Allanore\u00a0Y, Domsic\u00a0RT et\u00a0al (2024) A\u00a0randomised, parallel-group, double-blind, placebo-controlled phase\u00a03\u00a0study to Determine the effectiveness of the type\u00a0I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale. Clin Exp Rheumatol 42(8):1635\u20131644","journal-title":"Clin Exp Rheumatol"},{"key":"1925_CR66","unstructured":"Multicenter A (2020) Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis. https:\/\/clinicaltrials.gov\/study\/NCT04683029"},{"key":"1925_CR67","unstructured":"Randomized D\u2011b (2023) Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD). https:\/\/clinicaltrials.gov\/study\/NCT05892614"},{"issue":"1","key":"1925_CR68","first-page":"e2023011","volume":"40","author":"RP Baughman","year":"2023","unstructured":"Baughman\u00a0RP, Niranjan\u00a0V, Walker\u00a0G, Burkart\u00a0C, Paz\u00a0S, Chong\u00a0Y et\u00a0al (2023) Efzofitimod: a\u00a0novel anti-inflammatory agent for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 40(1):e2023011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"1925_CR69","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","volume":"11","author":"RJ Benschop","year":"2019","unstructured":"Benschop\u00a0RJ, Chow\u00a0CK, Tian\u00a0Y, Nelson\u00a0J, Barmettler\u00a0B, Atwell\u00a0S et\u00a0al (2019) Development of tibulizumab, a\u00a0tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs 11(6):1175\u20131190","journal-title":"mAbs"},{"key":"1925_CR70","unstructured":"Double Blind A (2022) Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240\/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD). https:\/\/clinicaltrials.gov\/study\/NCT05270668"},{"key":"1925_CR71","doi-asserted-by":"crossref","unstructured":"Khanna D, Evnin LB, Assassi S, Benton WW, Gordon G, Maslova K et\u00a0al (2024) Design of CONQUEST, a\u00a0novel, randomized, placebo-controlled, Phase\u00a02b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease. J\u00a0Scleroderma Relat Disord 23971983241278079:","DOI":"10.1177\/23971983241278079"},{"issue":"8","key":"1925_CR72","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann\u00a0C, M\u00fcller\u00a0F, Distler\u00a0JHW, Gy\u00f6rfi\u00a0AH, V\u00f6lkl\u00a0S, Aigner\u00a0M et\u00a0al (2023) Treatment of a\u00a0patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T\u00a0cells. Ann Rheum Dis 82(8):1117\u20131120","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1925_CR73","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth\u00a0J, M\u00fcller\u00a0F, V\u00f6lkl\u00a0S, Bayerl\u00a0N, Distler\u00a0JHW, Tur\u00a0C et\u00a0al (2025) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Lancet Rheumatol 7(2):e83\u2013e93","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"1925_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N\u00a0Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"key":"1925_CR75","doi-asserted-by":"crossref","unstructured":"Pecher A\u2011C, Hensen L, Schairer R, Klein R, Bethge W, Lengerke C et\u00a0al (2025) CD19-targeting CAR T\u00a0cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation. Eular Rheumatol Open","DOI":"10.1016\/j.ero.2025.03.005"},{"issue":"4","key":"1925_CR76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Freitag\u00a0M, Claus\u00a0M, Kolb\u00a0P, Falcone\u00a0V, R\u00f6hrich\u00a0M et\u00a0al (2024) Third-generation CD19.CAR-T\u00a0cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83(4):543\u2013546","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1925_CR77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","volume":"26","author":"M Claus","year":"2024","unstructured":"Claus\u00a0M, Freitag\u00a0M, Ewald\u00a0M, Rodon\u00a0L, Deicher\u00a0F, Watzl\u00a0C et\u00a0al (2024) Immunological effects of CD19.CAR-T\u00a0cell therapy in systemic sclerosis: an extended case study. Arthritis Res Ther 26(1):211","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1925_CR78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes\u00a0J, Oliveira\u00a0MC, Labopin\u00a0M, Badoglio\u00a0M, Scherer\u00a0HU, Del Papa\u00a0N, Daikeler\u00a0T, Schmalzing\u00a0M, Schroers\u00a0R, Martin\u00a0T, Pugnet\u00a0G, Simoes\u00a0B, Michonneau\u00a0D, Marijt\u00a0EWA, Lioure\u00a0B, Olivier Bay\u00a0J, Snowden\u00a0JA, Rovira\u00a0M, Huynh\u00a0A, Onida\u00a0F, Kanz\u00a0L, Marjanovic\u00a0Z, Farge\u00a0D (2021) Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica 106(2):375\u2013383. https:\/\/doi.org\/10.3324\/haematol.2019.230128","journal-title":"Haematologica"},{"key":"1925_CR79","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe\u00a0M, Magno\u00a0G, Gebhardt\u00a0C, B\u00fccklein\u00a0V, Szelinski\u00a0F, Ar\u00e9valo\u00a0HJR et\u00a0al (2024) Application of blinatumomab, a\u00a0bispecific anti-CD3\/CD19 T\u2011cell engager, in treating severe systemic sclerosis: A\u00a0case study. Eur J Cancer 204:114071","journal-title":"Eur J Cancer"},{"issue":"4","key":"1925_CR80","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","volume":"84","author":"E Siegert","year":"2025","unstructured":"Siegert\u00a0E, Biesen\u00a0R, Dzamukova\u00a0M, Furth\u00a0C, Probst\u00a0M, Doellinger\u00a0F et\u00a0al (2025) Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann Rheum Dis 84(4):653\u2013656","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1925_CR81","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen\u00a0M, Bucci\u00a0L, B\u00f6ltz\u00a0S, N\u00f6thling\u00a0DM, Rothe\u00a0T, Anoshkin\u00a0K (2024) BCMA-Targeted T\u2011Cell-Engager Therapy for Autoimmune Disease. N\u00a0Engl J Med 391(9):867\u2013869","journal-title":"N Engl J Med"},{"key":"1925_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.matbio.2017.12.016","volume":"68\u201369","author":"AH Gy\u00f6rfi","year":"2018","unstructured":"Gy\u00f6rfi\u00a0AH, Matei\u00a0AE, Distler\u00a0JHW (2018) Targeting TGF\u2011\u03b2 signaling for the treatment of fibrosis. Matrix Biol 68\u201369:8\u201327","journal-title":"Matrix Biol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01925-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:56:27Z","timestamp":1757206587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01925-1"}},"subtitle":["M\u00f6glichkeiten und Grenzen","Possibilities and limits"],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1925"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01925-1","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"16 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Dashi und C.\u00a0Bergmann geben an, dass kein Interessenkonflikt besteht. Forschungsf\u00f6rderung von Boehringer-Ingelheim (CB)\u00a0\u2013 nicht im Zusammenhang mit dem Inhalt des Artikels.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}